ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage biopharmaceutical company developing best in class oncology and CNS therapeutics, today announced that it has completed patient enrollment in its Phase IIa clinical trial evaluating the effectiveness of Serdaxin™ as a treatment for major depressive disorder (MDD).
